Introduced
Underlined text would be added to current law. Struck-through text would be removed.
| 89R1259 KKR-F | ||
| By: King | H.B. No. 3318 |
| A BILL TO BE ENTITLED | |
| AN ACT | |
| relating to access to individualized investigational treatments | |
| for patients with life-threatening or severely debilitating | |
| illnesses. | |
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | |
| SECTION 1. Subtitle C, Title 6, Health and Safety Code, is | |
| amended by adding Chapter 491 to read as follows: | |
| CHAPTER 491. ACCESS TO INDIVIDUALIZED INVESTIGATIONAL TREATMENTS | |
| FOR PATIENTS WITH LIFE-THREATENING OR SEVERELY DEBILITATING | |
| ILLNESSES | |
| SUBCHAPTER A. GENERAL PROVISIONS | |
| Sec. 491.001. DEFINITIONS. In this chapter: | |
| (1) "Individualized investigational treatment" means | |
| a drug, biological product, or device unique to and produced | |
| exclusively for use by a patient, based on the patient's genetic | |
| profile. The term includes individualized gene therapy antisense | |
| oligonucleotides and individualized neoantigen vaccines. | |
| (2) "Life-threatening illness" means a disease or | |
| condition with: | |
| (A) a significantly increased likelihood of | |
| death unless the course of the disease or condition is interrupted; | |
| or | |
| (B) potentially fatal outcomes and for which the | |
| goal of clinical trials is survival. | |
| (3) "Severely debilitating illness" means a disease or | |
| condition that causes major irreversible morbidity. | |
| SUBCHAPTER B. ACCESS TO INDIVIDUALIZED INVESTIGATIONAL TREATMENT | |
| Sec. 491.051. HEALTH CARE FACILITY ELIGIBILITY. A health | |
| care facility is eligible to provide an individualized | |
| investigational treatment under this chapter if the facility is | |
| operating under a federal assurance for the protection of human | |
| subjects under 42 U.S.C. Section 289(a) and 45 C.F.R. Part 46 and is | |
| subject to the federal assurance laws, regulations, policies, and | |
| guidelines. | |
| Sec. 491.052. PATIENT ELIGIBILITY. A patient is eligible | |
| to access an individualized investigational treatment under this | |
| chapter if: | |
| (1) the patient: | |
| (A) has a life-threatening illness or severely | |
| debilitating illness; | |
| (B) has considered all other treatment options | |
| currently approved by the United States Food and Drug | |
| Administration; and | |
| (C) has given written informed consent for access | |
| to the treatment; and | |
| (2) the patient's physician: | |
| (A) attests to the patient's life-threatening | |
| illness or severely debilitating illness and the patient's | |
| eligibility under this section; and | |
| (B) recommends the treatment for the patient | |
| based on analysis of the patient's genomic sequence, human | |
| chromosomes, deoxyribonucleic acid, ribonucleic acid, genes, gene | |
| products such as enzymes and other types of proteins, or | |
| metabolites. | |
| Sec. 491.053. INFORMED CONSENT. (a) An eligible patient | |
| may not access an individualized investigational treatment unless | |
| the patient provides written informed consent. If the patient is a | |
| minor or lacks the mental capacity to provide informed consent, a | |
| parent, legal guardian, managing conservator, or patient's agent as | |
| defined by Section 166.151 may provide written informed consent on | |
| the patient's behalf. | |
| (b) Informed consent under this chapter must be attested to | |
| in writing by the patient's physician and a witness. | |
| (c) Informed consent under this chapter must include at a | |
| minimum: | |
| (1) an explanation of the currently approved | |
| treatments for the patient's disease or condition; | |
| (2) the patient's attestation that the patient concurs | |
| with the assessment of the patient's physician that all currently | |
| approved and conventionally recognized treatments are unlikely to | |
| prolong the patient's life; | |
| (3) clear identification of the specific proposed | |
| individualized investigational drug, biological product, or device | |
| the patient's physician recommends; | |
| (4) a description, based on the physician's knowledge | |
| of the proposed treatment in conjunction with an awareness of the | |
| patient's disease or condition, of the potentially best and worst | |
| outcomes of using the treatment, and of the most likely outcome, | |
| including the possibility that new, unanticipated, different, or | |
| worse symptoms might result and that death could be hastened by the | |
| treatment; | |
| (5) a statement that the patient's health benefit plan | |
| issuer or third-party administrator and provider are not obligated | |
| to pay the cost of any care related to the use of the treatment | |
| unless payment is specifically required by law or contract; | |
| (6) a statement that the patient's eligibility for | |
| hospice care may be withdrawn if the patient begins the treatment | |
| and that care may be reinstated if the treatment ends and the | |
| patient meets hospice eligibility requirements; and | |
| (7) a statement that the patient understands the | |
| patient is liable for all expenses related to the use of the | |
| treatment and the liability extends to the patient's estate, unless | |
| a contract between the patient and the manufacturer of the | |
| treatment provides otherwise. | |
| Sec. 491.054. ACCESS TO TREATMENT; COSTS. (a) A | |
| manufacturer operating within an eligible health care facility and | |
| in compliance with all applicable federal assurance laws and | |
| regulations may make available an individualized investigational | |
| treatment, and an eligible patient may request access to the | |
| treatment from an eligible health care facility or manufacturer | |
| operating within an eligible health care facility under this | |
| chapter. | |
| (b) A manufacturer is not required under this chapter to | |
| make available an individualized investigational treatment to an | |
| eligible patient. | |
| (c) An eligible health care facility or manufacturer | |
| operating within an eligible health care facility may: | |
| (1) provide an individualized investigational | |
| treatment to an eligible patient without receiving compensation; or | |
| (2) require an eligible patient to pay the costs of, or | |
| the costs associated with, the manufacture of the treatment. | |
| Sec. 491.055. DEBT LIABILITY ON DEATH OF PATIENT. If a | |
| patient dies while receiving an individualized investigational | |
| treatment, the patient's heirs are not liable for any outstanding | |
| debt related to the treatment or lack of health coverage due to the | |
| treatment. | |
| Sec. 491.056. NO PRIVATE CAUSE OF ACTION. This chapter does | |
| not create a private cause of action against a manufacturer of an | |
| individualized investigational treatment or against any other | |
| person involved in the care of an eligible patient using the | |
| treatment for any harm to the patient resulting from the treatment | |
| if the manufacturer or other person is complying in good faith with | |
| the terms of this chapter and has exercised reasonable care. | |
| Sec. 491.057. PROHIBITED STATE INTERFERENCE WITH ACCESS TO | |
| TREATMENT. (a) An officer, employee, or agent of this state may | |
| not block or attempt to block an eligible patient's access to an | |
| individualized investigational treatment that complies with this | |
| chapter and rules adopted under this chapter. | |
| (b) Notwithstanding Subsection (a), counseling, advice, or | |
| a recommendation consistent with medical standards of care from a | |
| licensed health care provider is not a violation of this section. | |
| SUBCHAPTER C. HEALTH COVERAGE, COSTS, AND SERVICES | |
| Sec. 491.101. HEALTH COVERAGE. This chapter does not | |
| affect: | |
| (1) the coverage required of an insurer under the | |
| Insurance Code; or | |
| (2) health care coverage of enrollees in clinical | |
| trials under Chapter 1379, Insurance Code. | |
| Sec. 491.102. COVERAGE OPTIONAL. A health benefit plan | |
| issuer, third-party administrator, or governmental agency may, but | |
| is not required to, provide coverage for the cost of an | |
| individualized investigational treatment or the cost of services | |
| related to the use of an individualized investigational treatment | |
| under this chapter. | |
| Sec. 491.103. HOSPITAL SERVICES. This chapter does not | |
| require a hospital or health care facility licensed under Subtitle | |
| B, Title 4, to provide new or additional services unless approved by | |
| the hospital or facility. | |
| Sec. 491.104. GOVERNMENTAL AGENCY NOT RESPONSIBLE FOR | |
| COSTS. This chapter does not require a governmental agency to pay | |
| costs associated with the use, care, or treatment of a patient | |
| accessing an individualized investigational treatment. | |
| SUBCHAPTER D. HEALTH CARE PROVIDERS | |
| Sec. 491.151. PROHIBITED ACTION AGAINST LICENSE HOLDER OR | |
| MEDICAID PARTICIPANT. (a) A state licensing board may not revoke, | |
| fail to renew, suspend, or take any action against a health care | |
| provider's license issued under Title 3, Occupations Code, based | |
| solely on the provider's recommendation to an eligible patient | |
| regarding access to or treatment with an individualized | |
| investigational treatment. | |
| (b) The Health and Human Services Commission may not take | |
| action against a health care provider that adversely affects the | |
| provider's participation in Medicaid based solely on the provider's | |
| recommendation for a patient to access an individualized | |
| investigational treatment. | |
| SECTION 2. This Act takes effect September 1, 2025. |
Official text from the Texas Legislature. Formatting has been adapted for reading on Ratifi.